New CEO for Merz Therapeutics: Stefan König
As of immediately, Stefan König will be responsible for Merz Therapeutics GmbH as CEO and Managing Director. As one of the businesses of Merz Group, Merz Therapeutics provides medical solutions for the treatment of serious health conditions such as neurological health impairments or diseases of the liver.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005731/en/
Stefan Koenig, CEO Merz Therapeutics (Photo: Business Wire)
Stefan König is an accomplished leader who has successfully worked in the pharmaceutical industry for his entire career, both at national and international market level. “Merz Therapeutics has had a successful development in last years. That is why we are very pleased to have won an exceptional executive with Stefan König who will continue to expand our business and take it to the next level. His profound expert knowledge in both clinical-stage drug development and commercialization as well as his experience in different global markets make him the ideal person to drive the future growth strategy of Merz Therapeutics,” says Phillip Burchard, CEO of the Merz Group and Chairman of the Merz Holding Board.
Until recently, Stefan König held the position of President and CEO of George Medicines, a London-based company focusing on the development of pharmaceuticals in an advanced clinical phase. George Medicines is a spin-off of the George Institute, one of the leading international health research institutes. Before this, Stefan König worked for many years at Takeda Pharmaceuticals, where he held various senior positions in global, regional and local functions. Among others, he was responsible for the global Inflammatory Bowel Disease franchise, after heading up a number of local and regional market organizations.
After a strategic reorganization three years ago, Merz Group created Merz Therapeutics as one of its three core businesses, with the goal for each of the individual businesses to have a better focus on specific customers and markets. Since then, Merz Therapeutics has developed favourably. The previous CEO and Managing Director of Merz Therapeutics, Stefan Brinkmann, is leaving Merz by best mutual agreement at the end of February after many years. With Stefan König’s appointment as of March 1, 2023, we will ensure a seamless transition.
About the Merz Group
The Merz Group is a global, diversified health care company based in Frankfurt, Germany. Family-owned for over 110 years, the company is distinguished by its commitment to innovation, a long-term perspective, and a focus on sustainable, profitable growth. The Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, and Merz Financial Investments. The company employs 3,730 people (as of financial year 21/22) in 28 countries worldwide. To learn more, please visit www.merz.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005731/en/
Contact information
Merz Pharma GmbH & Co. KGaA
Communications
Karolina Dzeko-Balke
Telephone number: +49 (0) 69 1503 2749
E-mail: karolina.dzeko-balke@merz.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westlake Epoxy Promoting NEW AZURES™ Systems24.3.2023 13:00:00 EET | Press release
Westlake Corporation (NYSE: WLK) today announced that Westlake Epoxy will launch its new AZURES™ product range at the European Coatings Show 2023, to be held in Nuremberg, Germany, March 28 to 30, 2023. Westlake Epoxy’s Azures™ products are newly developed epoxy resins, modifiers and curing agents that are free of any SVHC- and CMR-labelled substances. As such, they provide better sustainable alternatives to existing technologies used in coatings, civil engineering and adhesives while keeping the same level of performance. “This is definitely another important milestone in Westlake Epoxy’s strategy to contribute to a safer and cleaner world,” said Ann Frederix, Vice President, Westlake Epoxy. Recently, Westlake Epoxy’s European business also confirmed its receipt of the 2022 Platinum Medal from EcoVadis, the world’s largest and most trusted provider of business sustainability ratings, and Westlake Epoxy’s Pernis, Netherlands site has successfully passed the audit for its International
Fischbein International and Votech Expand Manufacturing Footprint in Reusel and Announce New Company Name as Votech, a Duravant Company24.3.2023 11:00:00 EET | Press release
Votech announced today the grand opening of their newly expanded manufacturing facility and company headquarters in Reusel, The Netherlands. This marks the completed integration of two renowned leaders in the packaging industry, Fischbein International and Votech, who came together in 2021 through the acquisition of Votech by Duravant, a global engineered equipment and automation solutions provider to the Food Processing, Packaging and Material Handling sectors. The merger brought together 100+ years of packaging expertise and created a portfolio of technologies that expands the company’s ability to serve customers across a wide array of end markets including agriculture, animal nutrition, fruits and vegetables, ingredients, milk powders and other industrials. Alongside this announcement, the company unveiled their new company logo and brand campaign that reflects the organization’s transformation into a full-line packaging equipment provider. “The names Fischbein, Saxon and Votech, al
Smart DC, Building the Green Future | Huawei Unveils Top 10 Trends of Data Center Facilities24.3.2023 07:14:00 EET | Press release
Huawei recently held the Top 10 Trends of Data Center Facilities conference, themed "Smart DC, Building the Green Future". Fei Zhenfu, President of Huawei Data Center Facility Domain, released a white paper outlining Huawei's insights on data center facility trends that aim to promote sustainable development in the data center industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005815/en/ Fei Zhenfu, President of Huawei Data Center Facility Domain, shared Huawei's insights on the top 10 data center facility trends. (Photo: Business Wire) According to Mr. Fei, as global computing demand continues to grow exponentially in the digital intelligence era, there will be a surge in data center construction. To achieve carbon neutrality, the industry must prioritize energy conservation, carbon emission reduction, and green transformation. This presents both challenges and opportunities. Drawing from its experience and indu
HKSTP Reveals Startup Semi-finalists for Annual Global EPiC Pitch Competition24.3.2023 05:00:00 EET | Press release
Hong Kong is open to all and Hong Kong Science and Technology Parks Corporation (HKSTP) is ramping up its seventh Elevator Pitch Competition (EPiC 2023) by unveiling its 50 Grand Finale semi-finalists, selected from 618 entries and 55 economies across the world. EPiC 2023 -- backed by innovation-driven partners Cathay, HSBC, MTR Lab, plus world-leading accelerator Plug & Play -- is the city’s most eagerly anticipated pitch event each year and will take place on 28 April 2023 (Friday) at the summit of Hong Kong’s tallest building, the International Commerce Centre. The annual event is a unique, worldwide competition for mid to late-stage startups in the FinTech and PropTech sectors who seek to expand their footprints into Asia and beyond, while leveraging Hong Kong’s biggest innovation ecosystem at HKSTP. EPiC provides the best available platform for startups to make real business impact through connections with the Science Park network of 1,000+ investors and 300+ corporate partners. T
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets24.3.2023 03:55:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD). The complete response letter states that the FDA cannot approve the application in its present form. The FDA acknowledged that the study submitted in the New Drug Application (NDA) met its objective of bioequivalence based on area under the curve (AUC) parameters but identified additional requirements for approval. Incyte intends to meet with the FDA to determine appropriate next steps. “While we are disappointed that the FDA issued a complete response letter for ruxolitinib extended-release tablets, we remain committed to advancing care for people with myeloproliferative neoplasms and GVHD,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “We will w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom